Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy
Intervention:  
Sponsor:   Mayo Clinic
Recruiting

A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Conditions:   Dilated Cardiomyopathy;   Lamin A/C Gene Mutation
Interventions:   Drug: ARRY-371797;   Other: Placebo
Sponsor:   Array BioPharma
Recruiting

Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Condition:   Dilated Cardiomyopathy
Intervention:   Drug: Olmesartan 20 Mg Oral Tablet
Sponsor:   Dong-A University
Active, not recruiting

Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy

Condition:   Ischemic Cardiomyopathy
Interventions:   Biological: WJMSCs Vs. placebo;   Biological: Placebo
Sponsors:   Navy General Hospital, Beijing;   First People's Hospital of Foshan;   General Hospital of Armed Police, Beijing;   PLA General Hospital, Beijing
Not yet recruiting

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Condition:   Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions:   Drug: Vutrisiran;   Drug: Sterile Normal Saline (0.9% NaCl)
Sponsor:   Alnylam Pharmaceuticals
Recruiting

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis
Sponsor:   Pfizer
Recruiting

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

Condition:   Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Intervention:   Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy
Sponsor:   Pfizer
Recruiting

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Conditions:   Amyloidosis;   Amyloid Cardiomyopathy;   Transthyretin Amyloidosis;   Cardiomyopathies;   Heart Diseases
Interventions:   Drug: AG10;   Drug: Placebo Oral Tablet
Sponsor:   Eidos Therapeutics
Recruiting

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

Conditions:   Peripartum Cardiomyopathy;   Diastolic Dysfunction
Intervention:   Diagnostic Test: A clinical Transthoracic echocardiogram
Sponsors:   Sarah Thordsen;   Medical College of Wisconsin
Enrolling by invitation

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients With Non-Ischemic Cardiomyopathy

Conditions:   Cardiomyopathies;   Gender;   Implantable Defibrillator User
Intervention:  
Sponsors:   Biotronik, Inc.;   University of Rochester
Recruiting

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

Conditions:   Heart Failure;   Obesity;   Type 2 Diabetes Mellitus;   Health Normal Volunteer Subjects
Intervention:   Drug: [18F]FluorbetaOx
Sponsor:   Washington University School of Medicine
Completed

Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease

Conditions:   Dilated Cardiomyopathy;   Tricuspid Atresia
Intervention:   Device: Methacetin Breath Test (MBT)
Sponsor:   Northwestern University
Recruiting

Gene Therapy for Male Patients With Danon Disease Using RP-A501; AAV9.LAMP2B

Condition:   Danon Disease
Intervention:   Biological: RP-A501
Sponsor:   Rocket Pharmaceuticals Inc.
Recruiting

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Observational Hemodynamic Monitoring During LVAD Implantation Among Individuals With Advanced Heart Failure

Conditions:   Heart Failure;   Circulatory Disorders Postprocedural Complication;   Cardiomyopathy, Congestive;   Surgery
Intervention:  
Sponsor:   University of Colorado, Denver
Recruiting

Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients

Condition:   Hyperuricemia
Interventions:   Drug: Febuxostat;   Drug: Placebo
Sponsor:   Sun Yat-sen University
Recruiting

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.

Conditions:   Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency;   Carnitine-acylcarnitine Translocase (CACT) Deficiency
Intervention:   Drug: UX007
Sponsor:   Ultragenyx Pharmaceutical Inc
Enrolling by invitation

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Condition:   Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions:   Drug: Dapagliflozin;   Other: Placebo
Sponsor:   AstraZeneca
Recruiting

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Condition:   Heart Failure With Preserved Ejection Fraction
Interventions:   Drug: Macitentan;   Drug: Placebo
Sponsor:   Actelion
Recruiting

Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)

Conditions:   Chronic Kidney Disease;   Hemodialysis;   Hypertension
Interventions:   Device: Extra-vascular lung water measurements by ultrasound;   Other: Standard protocol of fluid management in hemodialysis
Sponsors:   Carmine Zoccali;   Aristotle University of Thessaloniki, Thessaloniki, Greece;   CNR-IBIM Clinical Epidemiology of Renal Diseases and Hypertension Unit, Reggio, Italy;   University Clinical Centre of Maribor, Slovenia
Completed

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

Condition:   Heart Failure
Interventions:   Device: V-Wave Interatrial Shunt;   Other: Control
Sponsor:   V-Wave Ltd
Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Conditions:   Cardiomyopathy;   Li-Fraumeni Syndrome;   Parkinson's Disease;   Atherosclerosis;   Cardiovascular Capacity
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Technical Development of Cardiovascular Magnetic Resonance Imaging

Conditions:   Cardiomyopathy;   Congenital Heart Disease;   Cardiovascular Disease;   Cardiac Magnetic Resonance Imaging;   Acute Myocardial Infarction
Intervention:   Device: Siemens MRI scanner
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended

Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness

Condition:   Pediatric or Young Adult Cancer Survivors
Interventions:   Genetic: Family History Questionnaire (FHQ);   Genetic: Salvia sample;   Other: Blood sample
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting

Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank

Conditions:   Sudden Cardiac Arrest;   Sudden Arrhythmic Death Syndrome;   Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC);   Long QT Syndrome (LQTS);   Hypertrophic Cardiomyopathy (HCM);   Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Intervention:  
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
Enrolling by invitation

Minimally Invasive Pericardiotomy as a New Treatment for Heart Failure

Condition:   Heart Failure
Intervention:   Procedure: Pericardiotomy
Sponsor:   Mayo Clinic
Active, not recruiting

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
Sponsors:   Amgen;   Cytokinetics;   Servier
Active, not recruiting

TRILUMINATE Pivotal Trial

Condition:   Tricuspid Regurgitation
Intervention:   Device: Tricuspid valve repair
Sponsor:   Abbott Medical Devices
Recruiting

HeartMapp: Assessment and Treatment for Heart Failure

Conditions:   Heart Failure;   Cognitive Impairment
Intervention:   Other: HeartMapp+CT
Sponsors:   Posit Science Corporation;   National Institute of Nursing Research (NINR);   University of South Florida
Recruiting

Intervention by a Cardiologist and Geriatrician in Elderly Patients After Admission Due to Heart Failure.

Condition:   Heart Failure
Interventions:   Other: Ambulatory visit;   Other: Combined ambulatory visit;   Other: Geriatric intervention
Sponsors:   Parc de Salut Mar;   Fundacion MAPFRE
Active, not recruiting

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Condition:   Heart Failure
Intervention:   Drug: LCZ696 (sacubitril/valsartan)
Sponsor:   Novartis Pharmaceuticals
Completed

REALIsM-HF Pilot Study

Condition:   Heart Failure
Interventions:   Device: VitalPatch Biosensor;   Device: DynaPort Move Monitor
Sponsor:   Bayer
Recruiting

Improving Sleep Quality in Heart Failure

Conditions:   Sleep Disturbance;   Heart Failure
Interventions:   Drug: Zolpidem Tartrate;   Drug: Placebo oral capsule
Sponsor:   Johns Hopkins University
Completed

Mid-Q Response Study

Conditions:   Heart Failure;   Left Bundle-Branch Block;   Heart Failure With Reduced Ejection Fraction (HFrEF);   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV
Interventions:   Device: aCRT ON;   Device: aCRT OFF
Sponsors:   Medtronic Bakken Research Center;   Medtronic;   Medtronic Japan Co., Ltd.
Not yet recruiting

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

Conditions:   Heart Failure With a Preserved Ejection Fraction;   Heart Failure, Diastolic;   Chronotropic Incompetence
Interventions:   Device: Rate adaptive atrial pacing using a dual-chamber pacemaker;   Device: Pacemaker system will be implanted but set to Pacing Off.
Sponsors:   Mayo Clinic;   Medtronic
Recruiting

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Conditions:   Aortic Valve Disease;   Aortic Valve Stenosis
Intervention:   Device: Foldax Tria Aortic Valve
Sponsor:   Foldax, Inc
Recruiting

PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study

Conditions:   Heart Failure;   Heart Failure With Preserved Ejection Fraction
Intervention:   Other: Extensive phenotyping
Sponsors:   Assistance Publique - Hôpitaux de Paris;   BPIfrance;   Sanofi;   Institut de Recherches Internationales Servier;   Institut National de la Santé Et de la Recherche Médicale, France;   BioSerenity;   Casis;   Firalis SA;   Fealinx;   Centre National de la Recherche Scientifique, France;   ESPCI Paris;   University of Paris 5 - Rene Descartes;   Sorbonne Université
Not yet recruiting

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

Conditions:   Heart Failure;   Diabetes Mellitus
Interventions:   Drug: Empagliflozin 10 MG;   Drug: Placebo Oral Tablet
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow
Active, not recruiting

ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement

Condition:   Aortic Stenosis
Interventions:   Device: ACURATE neo2™ Transfemoral TAVR System;   Device: Medtronic CoreValve TAVR System;   Device: Edwards SAPIEN 3 TAVR System
Sponsor:   Boston Scientific Corporation
Recruiting

MitraClip EXPAND G4 Study

Conditions:   Mitral Valve Regurgitation;   Mitral Regurgitation
Intervention:   Device: MitraClip G4 System
Sponsors:   Abbott Medical Devices;   Abbott
Not yet recruiting